Tango Therapeutics (TNGX) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $15.9 million.
- Tango Therapeutics' Income towards Parent Company rose 15445.88% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 1856.67%. This contributed to the annual value of -$130.3 million for FY2024, which is 2806.85% down from last year.
- Latest data reveals that Tango Therapeutics reported Income towards Parent Company of $15.9 million as of Q3 2025, which was up 15445.88% from -$38.9 million recorded in Q2 2025.
- Tango Therapeutics' 5-year Income towards Parent Company high stood at $15.9 million for Q3 2025, and its period low was -$39.9 million during Q1 2025.
- Its 5-year average for Income towards Parent Company is -$24.3 million, with a median of -$25.6 million in 2024.
- Per our database at Business Quant, Tango Therapeutics' Income towards Parent Company plummeted by 95180677.97% in 2021 and then skyrocketed by 15445.88% in 2025.
- Tango Therapeutics' Income towards Parent Company (Quarter) stood at -$22.1 million in 2021, then tumbled by 31.98% to -$29.1 million in 2022, then decreased by 5.65% to -$30.8 million in 2023, then decreased by 22.37% to -$37.6 million in 2024, then surged by 142.21% to $15.9 million in 2025.
- Its Income towards Parent Company stands at $15.9 million for Q3 2025, versus -$38.9 million for Q2 2025 and -$39.9 million for Q1 2025.